Chardan Capital Markets Raises Price Target on Amicus Therapeutics (FOLD); Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Leerink Partners Cuts Price Target on Amicus Therapeutics (FOLD) Following FDA Feedback
November 29, 2016 7:59 AM ESTLeerink Partners maintained an Outperform rating on Amicus Therapeutics (NASDAQ: FOLD), and cut the price target to $15.00 (from $17.00), following the company's announcement that the FDA feedback will lead to a new Galafold Ph.3 study slated to begin in 2017. Management will avoid disruptions to commercial launch in the EU and anticipates top-line data by 2019.... More
Amicus Therapeutics (FOLD): Revenue Loss from migalastat Drives PT Cut - Baird
November 29, 2016 7:00 AM ESTBaird analyst, Michael Ulz, reiterated his Neutral rating on shares of Amicus Therapeutics (NASDAQ: FOLD) and cut his price target to $7 from $9 after the company provided a disappointing update on the regulatory path forward for migalastat in the US. The company now requires an additional... More
After-Hours Stock Movers 09/01: (THO) (TIVO) (VNET) Higher; (NVLS) (FOLD) (SCVL) Lower (more...)
November 28, 2016 5:57 PM ESTToday's After-Hours Stock Movers
Nivalis Therapeutics (NASDAQ: NVLS) 53.6% LOWER; announced topline results from the Company's Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, 200 mg and 400 mg, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi. There were no dose limiting toxicities and cavosonstat was well tolerated at all doses in the trial. The trial failed, however, to demonstrate benefit in absolute change in percent predicted FEV1, the trials primary endpoint, or in sweat chloride reduction at 12... More
Amicus Therapeutics (FOLD) Reports Regulatory Pathway in U.S. for Migalastat for Fabry Disease
November 28, 2016 4:11 PM ESTAmicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of rare and orphan diseases, announces its planned regulatory pathway to collect additional data to support full approval for the oral precision medicine migalastat for Fabry disease. Following several collaborative discussions with the U.S. Food and Drug Administration (FDA), including the receipt of final written minutes from an in-person Type B meeting, the Company plans to collect additional data on gastrointestinal (GI) symptoms in Fabry patients who have an amenable mutation.
Key elements of the additional data... More
